GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00097436 | Stomach | GC | response to carbohydrate | 40/1159 | 253/18723 | 4.13e-08 | 2.85e-06 | 40 |
GO:0006639 | Stomach | GC | acylglycerol metabolic process | 24/1159 | 128/18723 | 9.59e-07 | 4.53e-05 | 24 |
GO:0006638 | Stomach | GC | neutral lipid metabolic process | 24/1159 | 129/18723 | 1.11e-06 | 5.20e-05 | 24 |
GO:0071356 | Stomach | GC | cellular response to tumor necrosis factor | 34/1159 | 229/18723 | 1.85e-06 | 8.24e-05 | 34 |
GO:00442424 | Stomach | GC | cellular lipid catabolic process | 32/1159 | 214/18723 | 3.16e-06 | 1.29e-04 | 32 |
GO:0034612 | Stomach | GC | response to tumor necrosis factor | 35/1159 | 253/18723 | 6.68e-06 | 2.54e-04 | 35 |
GO:0002237 | Stomach | GC | response to molecule of bacterial origin | 45/1159 | 363/18723 | 6.89e-06 | 2.57e-04 | 45 |
GO:00160425 | Stomach | GC | lipid catabolic process | 41/1159 | 320/18723 | 7.84e-06 | 2.80e-04 | 41 |
GO:0051235 | Stomach | GC | maintenance of location | 41/1159 | 327/18723 | 1.33e-05 | 4.35e-04 | 41 |
GO:0032496 | Stomach | GC | response to lipopolysaccharide | 41/1159 | 343/18723 | 4.09e-05 | 1.02e-03 | 41 |
GO:0019433 | Stomach | GC | triglyceride catabolic process | 9/1159 | 29/18723 | 4.19e-05 | 1.04e-03 | 9 |
GO:00620124 | Stomach | GC | regulation of small molecule metabolic process | 40/1159 | 334/18723 | 4.84e-05 | 1.15e-03 | 40 |
GO:0042632 | Stomach | GC | cholesterol homeostasis | 17/1159 | 96/18723 | 7.61e-05 | 1.64e-03 | 17 |
GO:00060665 | Stomach | GC | alcohol metabolic process | 41/1159 | 353/18723 | 7.85e-05 | 1.68e-03 | 41 |
GO:0055092 | Stomach | GC | sterol homeostasis | 17/1159 | 97/18723 | 8.70e-05 | 1.81e-03 | 17 |
GO:0055088 | Stomach | GC | lipid homeostasis | 24/1159 | 167/18723 | 9.86e-05 | 2.00e-03 | 24 |
GO:0019216 | Stomach | GC | regulation of lipid metabolic process | 37/1159 | 331/18723 | 3.67e-04 | 5.70e-03 | 37 |
GO:0046461 | Stomach | GC | neutral lipid catabolic process | 9/1159 | 39/18723 | 5.06e-04 | 7.16e-03 | 9 |
GO:0046464 | Stomach | GC | acylglycerol catabolic process | 9/1159 | 39/18723 | 5.06e-04 | 7.16e-03 | 9 |
GO:0046890 | Stomach | GC | regulation of lipid biosynthetic process | 22/1159 | 171/18723 | 8.94e-04 | 1.10e-02 | 22 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa049796 | Liver | NAFLD | Cholesterol metabolism | 20/1043 | 51/8465 | 9.73e-07 | 4.56e-05 | 3.67e-05 | 20 |
hsa0541714 | Liver | NAFLD | Lipid and atherosclerosis | 42/1043 | 215/8465 | 1.46e-03 | 1.71e-02 | 1.38e-02 | 42 |
hsa0497911 | Liver | NAFLD | Cholesterol metabolism | 20/1043 | 51/8465 | 9.73e-07 | 4.56e-05 | 3.67e-05 | 20 |
hsa0541715 | Liver | NAFLD | Lipid and atherosclerosis | 42/1043 | 215/8465 | 1.46e-03 | 1.71e-02 | 1.38e-02 | 42 |
hsa049792 | Liver | Cirrhotic | Cholesterol metabolism | 30/2530 | 51/8465 | 1.59e-05 | 1.39e-04 | 8.60e-05 | 30 |
hsa0541722 | Liver | Cirrhotic | Lipid and atherosclerosis | 80/2530 | 215/8465 | 1.18e-02 | 3.81e-02 | 2.35e-02 | 80 |
hsa049793 | Liver | Cirrhotic | Cholesterol metabolism | 30/2530 | 51/8465 | 1.59e-05 | 1.39e-04 | 8.60e-05 | 30 |
hsa0541732 | Liver | Cirrhotic | Lipid and atherosclerosis | 80/2530 | 215/8465 | 1.18e-02 | 3.81e-02 | 2.35e-02 | 80 |
hsa049794 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
hsa049795 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
hsa0541712 | Stomach | GC | Lipid and atherosclerosis | 40/708 | 215/8465 | 1.01e-06 | 1.80e-05 | 1.27e-05 | 40 |
hsa04975 | Stomach | GC | Fat digestion and absorption | 14/708 | 43/8465 | 5.71e-06 | 8.30e-05 | 5.84e-05 | 14 |
hsa0541713 | Stomach | GC | Lipid and atherosclerosis | 40/708 | 215/8465 | 1.01e-06 | 1.80e-05 | 1.27e-05 | 40 |
hsa049751 | Stomach | GC | Fat digestion and absorption | 14/708 | 43/8465 | 5.71e-06 | 8.30e-05 | 5.84e-05 | 14 |
hsa0541710 | Stomach | SIM | Lipid and atherosclerosis | 34/465 | 215/8465 | 1.80e-08 | 4.20e-07 | 3.37e-07 | 34 |
hsa049752 | Stomach | SIM | Fat digestion and absorption | 12/465 | 43/8465 | 2.11e-06 | 3.05e-05 | 2.45e-05 | 12 |
hsa04979 | Stomach | SIM | Cholesterol metabolism | 8/465 | 51/8465 | 6.17e-03 | 3.83e-02 | 3.08e-02 | 8 |
hsa0541711 | Stomach | SIM | Lipid and atherosclerosis | 34/465 | 215/8465 | 1.80e-08 | 4.20e-07 | 3.37e-07 | 34 |
hsa049753 | Stomach | SIM | Fat digestion and absorption | 12/465 | 43/8465 | 2.11e-06 | 3.05e-05 | 2.45e-05 | 12 |
hsa049791 | Stomach | SIM | Cholesterol metabolism | 8/465 | 51/8465 | 6.17e-03 | 3.83e-02 | 3.08e-02 | 8 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
APOB | SNV | Missense_Mutation | novel | c.8392G>C | p.Glu2798Gln | p.E2798Q | P04114 | protein_coding | tolerated(0.3) | benign(0.138) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
APOB | SNV | Missense_Mutation | novel | c.13546N>A | p.Glu4516Lys | p.E4516K | P04114 | protein_coding | tolerated(0.1) | possibly_damaging(0.485) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
APOB | SNV | Missense_Mutation | | c.7482N>G | p.Asn2494Lys | p.N2494K | P04114 | protein_coding | tolerated(0.35) | benign(0.031) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
APOB | SNV | Missense_Mutation | rs371177562 | c.12677C>T | p.Thr4226Met | p.T4226M | P04114 | protein_coding | deleterious(0.04) | benign(0) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
APOB | SNV | Missense_Mutation | | c.10418N>T | p.Ala3473Val | p.A3473V | P04114 | protein_coding | deleterious(0.05) | benign(0.047) | TCGA-A7-A3RF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
APOB | SNV | Missense_Mutation | | c.8477N>G | p.Glu2826Gly | p.E2826G | P04114 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A06T-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
APOB | SNV | Missense_Mutation | | c.5615N>A | p.Ile1872Asn | p.I1872N | P04114 | protein_coding | deleterious(0) | probably_damaging(0.913) | TCGA-A8-A08O-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | PD |
APOB | SNV | Missense_Mutation | | c.12526N>A | p.Val4176Ile | p.V4176I | P04114 | protein_coding | tolerated(1) | benign(0.001) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
APOB | SNV | Missense_Mutation | | c.2266N>T | p.Leu756Phe | p.L756F | P04114 | protein_coding | tolerated(0.72) | benign(0.001) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
APOB | SNV | Missense_Mutation | | c.9739N>G | p.Gln3247Glu | p.Q3247E | P04114 | protein_coding | tolerated(0.12) | benign(0.127) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | ETHANOL | ALCOHOL | 8576634 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | LOVASTATIN | LOVASTATIN | 2351867,7662319,1588827 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | LIGNAN | | 15671223 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | TKM-APOB | | |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | QUERCETIN | QUERCETIN | 16149735 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | lomitapide | LOMITAPIDE | |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | EPIGALLOCATECHIN GALLATE | | 11936850 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | PRAVASTATIN | PRAVASTATIN | 8312689 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | warfarin | WARFARIN | |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | DEXAMETHASONE | DEXAMETHASONE | 7670964 |